Oppenheimer has raised its Exelixis Inc. price target to $29 from $25, citing the biotech’s Phase 3 CONTACT-02 trial evaluating Cabozantinib in combination...
Oppenheimer has raised its Exelixis Inc.
price target to $29 from $25, citing the biotech’s Phase 3 CONTACT-02 trial evaluating Cabozantinib in combination with Atezolizumab.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Goldman Sachs may sell unit with $29 billion in assetsGoldman Sachs said Monday it's considering the sale of part of its wealth-management division.
続きを読む »
$29 Target massager has shoppers in hysterics for resemblance to certain X-rated toyThe retail giant’s Sharper Image Personal Touch Go Massager looks an awful lot like the popular $240 Magic Wand vibrator, leaving people wondering if it is in fact a dupe or just a funny coin…
続きを読む »
Box Office: ‘Blue Beetle’ Stumbles With $25 Million Debut, Ends ‘Barbie’s’ Four-Week Streak“Blue Beetle” has dethroned “Barbie” at the domestic box office. The latest DC superhero adventure claimed the No. 1 spot despite a softer-than-expected debut of $25.4 million. &…
続きを読む »
Biden campaign announces $25 million ad buy targeting Hispanic and black votersPresident Joe Biden’s reelection campaign announced a massive ad buy Saturday morning.
続きを読む »
Biden Campaign Pours $25 Million into Swing State Ad BlitzPresident Joe Biden’s campaign is shelling out $25 million for a four-months-long ad campaign in swing states as he polls tight with Trump.
続きを読む »